Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study

Bibliographic Details
Title: Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study
Authors: Malcolm West, Adrienne Kirby, Ralph A. Stewart, Stefan Blankenberg, David Sullivan, Harvey D. White, David Hunt, Ian Marschner, Edward Janus, Leonard Kritharides, Gerald F. Watts, John Simes, Andrew M. Tonkin
Source: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 5 (2022)
Publisher Information: Wiley, 2022.
Publication Year: 2022
Collection: LCC:Diseases of the circulatory (Cardiovascular) system
Subject Terms: biomarkers, cardiovascular disease, chronic kidney disease, coronary disease, cystatin C, hydroxymethylglutaryl‐CoA reductase inhibitors, Diseases of the circulatory (Cardiovascular) system, RC666-701
More Details: Background Elevated plasma cystatin C levels reflect reduced renal function and increased cardiovascular risk. Less is known about whether the increased risk persists long‐term or is independent of renal function and other important biomarkers. Methods and Results Cystatin C and other biomarkers were measured at baseline (in 7863 patients) and 1 year later (in 6106 patients) in participants in the LIPID (Long‐Term Intervention with Pravastatin in Ischemic Disease) study, who had a previous acute coronary syndrome. Outcomes were ascertained during the study (median follow‐up, 6 years) and long‐term (median follow‐up, 16 years). Glomerular filtration rate (GFR) was estimated using Chronic Kidney Disease Epidemiology Collaboration equations (first GFR‐creatinine, then GFR‐creatinine‐cystatin C). Over 6 years, in fully adjusted multivariable time‐to‐event models, with respect to the primary end point of coronary heart disease mortality or nonfatal myocardial infarction, for comparison of Quartile 4 versus 1 of baseline cystatin C, the hazard ratio was 1.37 (95% CI, 1.07–1.74; P=0.01), and for major cardiovascular events was 1.47 (95% CI, 1.19–1.82; P
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2047-9980
Relation: https://doaj.org/toc/2047-9980
DOI: 10.1161/JAHA.121.020745
Access URL: https://doaj.org/article/3fc3a289c08246f98eb117bce6e71980
Accession Number: edsdoj.3fc3a289c08246f98eb117bce6e71980
Database: Directory of Open Access Journals
More Details
ISSN:20479980
DOI:10.1161/JAHA.121.020745
Published in:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Language:English